France's Erytech Closer To Realizing Market Ambitions With Eryaspase US Filing

Positive FDA Feedback For Leukemia Submission

23 Jul 2021

It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.

folders — Erytech sorting submission out for eryaspase • Source: Archive

Founded in 2004, ERYTECH Pharma S.A. is finally closing in on getting a product to market after talks with regulators in the US laid an approval pathway for the French biotech's lead candidate eryaspase.

The Paris-headquartered firm is looking to submit eryaspase, which consists of the enzyme L-asparaginase (L-ASP) that is encapsulated inside donor-derived red blood cells, to the US Food and Drug Administration in the fourth quarter for hypersensitive acute lymphoblastic leukemia (ALL)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

15 May 2025

• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.